| abstract |
The present invention provides compositions and methods for treating diseases associated with CD19 expression. The present invention also relates to the use of a humanized anti-CD19 single-chain antibody with low immunogenicity as a CD19 antigen-binding fragment for constructing a chimeric antigen receptor (CAR) specific to CD19, a vector encoding it, and an anti-CD19-containing antibody. Recombinant T cells with CD19CAR. The invention also includes methods of administering genetically modified T cells expressing a CAR comprising a humanized anti-CD19 antigen-binding fragment. |